[{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"MBX 2109","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Series C Financing","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0.059999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Deep Track Capital","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Deep Track Capital"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0.16,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0.19,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0.16,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0.19,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0.19,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0.19,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0.19,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"MBX 1416","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"ProSciento","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"MBX 1416","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"MBX Biosciences \/ ProSciento","highestDevelopmentStatusID":"6","companyTruncated":"MBX Biosciences \/ ProSciento"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"MBX 1416","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"MBX 1416","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Wellington Management","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Series B Financing","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0.12,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Wellington Management","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Wellington Management"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"MBX 1416","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MBX 4291","moa":"GIPR \/GLP-1","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MBX2109","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MBX-2109","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MBX2109","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"MBX Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"MBX Biosciences \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"4","companyTruncated":"MBX Biosciences \/ Frazier Healthcare Partners"}]
Find Clinical Drug Pipeline Developments & Deals by MBX Biosciences
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
